Daniel Ebner
Research groups
Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
The changing face of UK academic drug screening in the past decade
Journal article
Baronio R. and Ebner D., (2026), Nature Reviews Drug Discovery
A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.
Journal article
Elliott RJR. et al, (2026), iScience, 29
Refined USP25/28 inhibitors with enhanced selectivity towards c-Myc driven squamous lung cancer cells
Preprint
Pinto-Fernández A. et al, (2026)
Therapeutic targeting of SETD2-deficient cancer cells with the small-molecule compound RITA
Preprint
Humphrey T. et al, (2026)
SoftHybrid: A Hybrid Imputation Algorithm Optimised for Single-Cell Proteomics Data
Preprint
Shi Y. et al, (2026)